Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology, Veterans Health Administration, Philadelphia, Pennsylvania.
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2817-2824.e4. doi: 10.1016/j.cgh.2023.03.012. Epub 2023 Mar 24.
BACKGROUND & AIMS: Antibiotic exposure leads to changes in the gut microbiota. Our objective was to evaluate the association between antibiotic exposure and esophageal adenocarcinoma (EAC) risk.
We performed a nested case-control study using data from the Veterans Health Administration from 2004 through 2020. The case group consisted of patients who received an incident diagnosis of EAC. For each case, up to 20 matched controls were selected using incidence density sampling. Our primary exposure of interest was any oral or intravenous antibiotic use. Our secondary exposures included cumulative number of days of exposure and classification of antibiotics by various subgroups. Conditional logistic regression was used to estimate the crude and adjusted odds ratios (aORs) for the risk of EAC associated with antibiotic exposure.
The case-control analysis included 8226 EAC cases and 140,670 matched controls. Exposure to any antibiotic was associated with an aOR for EAC of 1.74 (95% confidence interval [CI], 1.65-1.83) vs no antibiotic exposure. Compared with no antibiotic exposure, the aOR for EAC was 1.63 (95% CI, 1.52-1.74; P < .001) for cumulative exposure to any antibiotic for 1 to 15 days; 1.77 (95% CI, 1.65-1.89; P < 0 .001) for 16 to 47 days; and 1.87 (95% CI, 1.75-2.01; P < .001) for ≥48 days, respectively (P for trend < .001).
Exposure to any antibiotic is associated with an increased risk of EAC, and this risk increases as the cumulative days of exposure increase. This novel finding is hypothesis-generating for potential mechanisms that may play a role in the development or progression of EAC.
抗生素暴露会导致肠道微生物群发生变化。我们的目的是评估抗生素暴露与食管腺癌(EAC)风险之间的关联。
我们使用 2004 年至 2020 年期间退伍军人健康管理局的数据进行了一项嵌套病例对照研究。病例组由接受 EAC 新发病例诊断的患者组成。对于每个病例,使用发病率密度抽样选择最多 20 名匹配对照。我们主要关注的暴露因素是口服或静脉内使用任何抗生素。我们的次要暴露因素包括暴露天数的累积数和按各种亚组分类的抗生素。使用条件逻辑回归来估计与抗生素暴露相关的 EAC 风险的粗比值比(OR)和调整比值比(aOR)。
病例对照分析包括 8226 例 EAC 病例和 140670 例匹配对照。与未使用抗生素相比,使用任何抗生素与 EAC 的 aOR 为 1.74(95%置信区间[CI],1.65-1.83)。与未使用抗生素相比,使用任何抗生素的累积暴露 1 至 15 天的 EAC 的 aOR 为 1.63(95%CI,1.52-1.74;P <.001);16 至 47 天的 aOR 为 1.77(95%CI,1.65-1.89;P < 0.001);≥48 天的 aOR 为 1.87(95%CI,1.75-2.01;P <.001)(P 趋势<.001)。
暴露于任何抗生素与 EAC 的风险增加相关,并且这种风险随着暴露天数的增加而增加。这一新发现为可能在 EAC 发生或进展中发挥作用的潜在机制提供了假设。